Here are the 10-K annual reports from Shoulder Innovations, Inc. (SI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow SI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SI filings page.
Shoulder Innovations, Inc. files its annual report describing a commercial-stage medical technology business focused solely on shoulder surgical care. The company sells advanced anatomic and reverse shoulder implant systems, its AI-enabled ProVoyance planning software, and a two-tray instrument platform designed to simplify procedures, especially in outpatient surgery centers.
Management estimates about 250,000 U.S. shoulder arthroplasty procedures in 2025, an approximately $1.7 billion market, and a global opportunity of about $2.7 billion growing roughly 11% annually through 2029. Its implants have been used in more than 17,500 procedures, with clinical studies showing long-term durability of the InSet Glenoid design.
The report highlights a specialized sales model targeting roughly 1,800 high-volume U.S. surgeons, strong adoption of ProVoyance in virtually all Shoulder Innovations cases, and a 50% increase in procedure volume from 2024 to 2025. As of March 3, 2026, the company had 20,647,526 common shares outstanding and continues to expand its product pipeline, including metal-sensitive implants, fracture and revision solutions, and a developing shoulder-specific robotics platform.